Related Experiment Video
Updated: Aug 8, 2026

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time
Published on: May 20, 2014
Sustained complete remission in a patient with platinum-resistant ovarian yolk sac tumor
A Jeyakumar1, E Chalas, A Hindenburg
1Oncology/Hematology Division, Department of Medicine, Winthrop University Hospital, Mineola, New York 11501, USA. alwinj@excite.com
Background:
Yolk sac tumors of the ovary are generally very responsive to chemotherapy; however, they are difficult to manage in the setting of platinum resistance where treatment options are limited and outcomes are poorer.
Case:
We present a 39-year-old woman who had a platinum-resistant yolk sac ovarian tumor. She achieved complete remission on an innovative regimen of docetaxel, gemcitabine, and thalidomide.
Conclusion:
The combination of docetaxel, gemcitabine, and thalidomide might be an active regimen for platinum-resistant ovarian nondysgerminomas and further investigation of this combination is warranted.
Related Concept Videos
Treatment Resistant Cancers
Treatment Resistent Cancers

